|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01578 |
Gene summary for LINC01578 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01578 | Gene ID | 100507217 |
| Gene name | CHD2 adjacent suppressive regulatory RNA | |
| Gene Alias | LINC01578 | |
| Cytomap | 15q26.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100507217 | LINC01578 | CCI_2 | Human | Cervix | CC | 1.93e-04 | 2.26e-01 | 0.5249 |
| 100507217 | LINC01578 | sample1 | Human | Cervix | CC | 5.15e-21 | 5.03e-01 | 0.0959 |
| 100507217 | LINC01578 | sample3 | Human | Cervix | CC | 1.15e-54 | 6.64e-01 | 0.1387 |
| 100507217 | LINC01578 | H2 | Human | Cervix | HSIL_HPV | 8.09e-39 | 6.37e-01 | 0.0632 |
| 100507217 | LINC01578 | L1 | Human | Cervix | CC | 1.36e-14 | 5.59e-01 | 0.0802 |
| 100507217 | LINC01578 | T1 | Human | Cervix | CC | 4.31e-32 | 5.61e-01 | 0.0918 |
| 100507217 | LINC01578 | T2 | Human | Cervix | CC | 5.55e-34 | 8.77e-01 | 0.0709 |
| 100507217 | LINC01578 | T3 | Human | Cervix | CC | 9.62e-53 | 6.52e-01 | 0.1389 |
| 100507217 | LINC01578 | AEH-subject1 | Human | Endometrium | AEH | 1.77e-44 | 7.28e-01 | -0.3059 |
| 100507217 | LINC01578 | AEH-subject2 | Human | Endometrium | AEH | 4.57e-31 | 6.20e-01 | -0.2525 |
| 100507217 | LINC01578 | AEH-subject3 | Human | Endometrium | AEH | 1.17e-28 | 5.64e-01 | -0.2576 |
| 100507217 | LINC01578 | AEH-subject4 | Human | Endometrium | AEH | 4.89e-49 | 9.04e-01 | -0.2657 |
| 100507217 | LINC01578 | AEH-subject5 | Human | Endometrium | AEH | 8.08e-46 | 6.99e-01 | -0.2953 |
| 100507217 | LINC01578 | EEC-subject1 | Human | Endometrium | EEC | 3.80e-37 | 6.17e-01 | -0.2682 |
| 100507217 | LINC01578 | EEC-subject2 | Human | Endometrium | EEC | 1.02e-26 | 4.95e-01 | -0.2607 |
| 100507217 | LINC01578 | EEC-subject3 | Human | Endometrium | EEC | 1.58e-12 | 3.32e-01 | -0.2525 |
| 100507217 | LINC01578 | EEC-subject4 | Human | Endometrium | EEC | 3.14e-30 | 5.54e-01 | -0.2571 |
| 100507217 | LINC01578 | EEC-subject5 | Human | Endometrium | EEC | 2.08e-38 | 6.00e-01 | -0.249 |
| 100507217 | LINC01578 | S41 | Human | Liver | Cirrhotic | 2.37e-02 | 3.26e-01 | -0.0343 |
| 100507217 | LINC01578 | HCC1 | Human | Liver | HCC | 4.11e-14 | 2.86e+00 | 0.5336 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |